Tvardi Therapeutics, Inc. (TVRD) Q3 2025 10-Q Quarterly Report
Tvardi Therapeutics, Inc. (TVRD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Tvardi Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New clinical trial data risk: Phase 2 trial of TTI-101 in IPF failed primary goals as of October 2025, triggering additional analyses and uncertain next steps
- • Most materially updated financial risk: Cash and equivalents $21.4M, short-term investments $15.0M as of Sept 30, 2025, significant doubt about going concern status
Tvardi Therapeutics, Inc. Q3 2025 Quarterly FinancialsXBRL
Net Income
-$6M
▲ +55.7% YoY▼ -992.3% QoQ
ROE
-19.8%
Total Assets
$39M
EPS (Diluted)
$-0.46
▼ -109.1% YoY▼ -139.0% QoQ
Operating Cash Flow
-$4M
▲ +69.6% YoY▲ +52.0% QoQ
Source: XBRL data from Tvardi Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Tvardi Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.